Tony, I disagreee. the patent moat is very painfully obvious to our competition and the shorts. They're in the business to know and understand such things. It won't be so obvious to the casual retail buyer of our stock, but serious investors who do their research will understand. However, I'm sure the shorts will ignore our strong patent protections and continue to blast the stock in a last ditch effort to squeeze out every penny before the dam breaks on our price.
BTW, this is the PR I've been waiting and had hoped/expected would hit before commercial approval. Now we know NWBO is ready for the Big Leagues. Approval of Flaskworks has been successfully optimized and is coming soon, whether that timeline is a month, six months, or a year. In the near future we will be ready to serve not only all the brain tumor market (which might include grade 3) in multiple countries that have reciprical medicine approval agreements with the UK, but all cancers where patients are willing to use it off label.
Finally, what I got from the PR (which I've only just gotten home and read once) is that Flaskworks is on its own approval schedule, which is good. We don't want the market approval being held up while we wait for the new Flaskworks' manufacturer to begin production and to test the manufacturer's first units for approval. But who knows...maybe it will happen quickly. I would not be surprised to see DCVax-L approved at the March 21-22 meeting of MHRA. We already know they recently recertified several areas related to manufacturing and storage of human tissue, which I gathered are on the MAA application check-off list.
Congrats to NWBO and Advent employees!
Bullish
AI
Market Data 
Markets 
